These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25088750)

  • 1. Encompassing receptor flexibility in virtual screening using ensemble docking-based hybrid QSAR: discovery of novel phytochemicals for BACE1 inhibition.
    Chakraborty S; Ramachandran B; Basu S
    Mol Biosyst; 2014 Oct; 10(10):2684-92. PubMed ID: 25088750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
    Chakraborty S; Kumar S; Basu S
    Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target specific proteochemometric model development for BACE1 - protein flexibility and structural water are critical in virtual screening.
    Manoharan P; Chennoju K; Ghoshal N
    Mol Biosyst; 2015 Jul; 11(7):1955-72. PubMed ID: 25927726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
    Kumar A; Roy S; Tripathi S; Sharma A
    J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors.
    Vijayan RS; Prabu M; Mascarenhas NM; Ghoshal N
    J Chem Inf Model; 2009 Mar; 49(3):647-57. PubMed ID: 19434899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction mechanism exploration of HEA derivatives as BACE1 inhibitors by in silico analysis.
    Wu Q; Li X; Gao Q; Wang J; Li Y; Yang L
    Mol Biosyst; 2016 Apr; 12(4):1151-65. PubMed ID: 26915506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
    Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
    J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.
    Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein flexibility in ligand docking and virtual screening to protein kinases.
    Cavasotto CN; Abagyan RA
    J Mol Biol; 2004 Mar; 337(1):209-25. PubMed ID: 15001363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations.
    Xu Y; Li MJ; Greenblatt H; Chen W; Paz A; Dym O; Peleg Y; Chen T; Shen X; He J; Jiang H; Silman I; Sussman JL
    Acta Crystallogr D Biol Crystallogr; 2012 Jan; 68(Pt 1):13-25. PubMed ID: 22194329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process.
    Gueto-Tettay C; Martinez-Consuegra A; Zuchniarz J; Gueto-Tettay LR; Drosos-Ramírez JC
    J Mol Graph Model; 2017 Sep; 76():274-288. PubMed ID: 28746905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
    Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
    Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study.
    Ahmad SS; Akhtar S; Danish Rizvi SM; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):311-318. PubMed ID: 28413992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative molecular dynamics study on BACE1 and BACE2 flap flexibility.
    Kumalo HM; Soliman ME
    J Recept Signal Transduct Res; 2016 Oct; 36(5):505-14. PubMed ID: 26804314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening and structure-based discovery of indole acylguanidines as potent β-secretase (BACE1) inhibitors.
    Zou Y; Li L; Chen W; Chen T; Ma L; Wang X; Xiong B; Xu Y; Shen J
    Molecules; 2013 May; 18(5):5706-22. PubMed ID: 23681056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-target screening mines hesperidin as a multi-potent inhibitor: Implication in Alzheimer's disease therapeutics.
    Chakraborty S; Bandyopadhyay J; Chakraborty S; Basu S
    Eur J Med Chem; 2016 Oct; 121():810-822. PubMed ID: 27068363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavonoids as BACE1 inhibitors: QSAR modelling, screening and in vitro evaluation.
    Das S; Majumder T; Sarkar A; Mukherjee P; Basu S
    Int J Biol Macromol; 2020 Dec; 165(Pt A):1323-1330. PubMed ID: 33010267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid approach to sieve out natural compounds against dual targets in Alzheimer's Disease.
    Das S; Chakraborty S; Basu S
    Sci Rep; 2019 Mar; 9(1):3714. PubMed ID: 30842555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking.
    Huang D; Liu Y; Shi B; Li Y; Wang G; Liang G
    J Mol Graph Model; 2013 Sep; 45():65-83. PubMed ID: 24004830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protonation states of the catalytic dyad of β-secretase (BACE1) in the presence of chemically diverse inhibitors: a molecular docking study.
    Barman A; Prabhakar R
    J Chem Inf Model; 2012 May; 52(5):1275-87. PubMed ID: 22545704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.